Current and future challenges in therapy for antibody-mediated rejection

Area of Science:

• Cardiology
• Immunology
• Transplantation

Background:

• Antibody-mediated rejection (AMR) poses a significant threat to cardiac allograft survival.
• Rising incidence of AMR is linked to evolving transplantation practices and improved acute cellular rejection therapies.
• Chronic AMR treatment remains poorly defined and challenging compared to acute AMR.

Purpose of the Study:

• To review the challenges associated with treating antibody-mediated rejection in cardiac transplantation.
• To critically analyze current and potential future therapeutic interventions for AMR.

Main Methods:

• Literature review of current and emerging therapies for antibody-mediated rejection.
• Analysis of the antibody response pathway for potential therapeutic targets.
• Discussion of treatment strategies including immunosuppression, antibody elimination, and tolerance induction.

Main Results:

• AMR is often more severe and less responsive to standard immunosuppression than cellular rejection.
• The antibody response offers multiple targets for intervention, including T and B cell suppression, antibody elimination, and inhibition.
• A multi-drug regimen approach appears most effective for managing AMR.

Conclusions:

• Effective management of AMR requires addressing its complexity and developing targeted therapies.
• Future strategies may involve inducing tolerance or achieving accommodation with robust immune surveillance.
• Further research into novel treatments is crucial for improving long-term cardiac allograft survival.